1.Alternative Name：TNFSF7,CD27LG；CD27 Ligand; CD27-L; CD27LCD27 ligand; CD27LG; CD70 molecule; CD70; Ki-24 antigen; surface antigen CD70; TNFSF7; TNFSF7CD70 antigen; tumor necrosis factor (ligand) superfamily, member 7; Tumor necrosis factor ligand superfamily member 7
2.Target：CD70
3.Source：Human CD70 was expressed from HEK293 with human IgG1 FC at the C-terminal
4.Sequence：Ser52-Pro193
5.Protein structure:：P32970hFC
6.Molecular Characterization:The protein has a calculated MW of 50kDa.The non-reducing (N-R) heterodimer protein migrates as 50-70 kDa due to glycosylation
7.Purity:SDS-PAGE>90%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 95%.

12.SEC-HPLC

Determined by SEC-HPLC, the purity of the protein is greater than 95%.

13.ELISA

When Recombinant Human CD70/ His Flag Protein is immobilized at 5μg/mL (100 μL/well), the concentration of Anti-Human CD70 (Cusatuzumab) that produces 50% of the optimal binding response is approximately 10 ug/ml.

14.Note:For Research Use Only.